Westwood Holdings Group’s Prime Medicine PRME Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-883,129
Closed -$2.58M 500
2024
Q4
$2.58M Buy
883,129
+433,653
+96% +$1.52M 0.02% 298
2024
Q3
$1.74M Buy
449,476
+90,896
+25% +$421K 0.01% 348
2024
Q2
$1.84M Buy
358,580
+199,229
+125% +$1.21M 0.01% 324
2024
Q1
$1.11M Buy
+159,351
New +$1.21M 0.01% 354

Other funds holding PRME

Westwood Holdings Group's PRME Position: Q1 2025 in Review

Westwood Holdings Group sold out of Prime Medicine (PRME) in Q1 2025, closing a stake of 883,129 shares — an estimated $2.58M sold.

Westwood Holdings Group first reported a position in PRME in Q1 2024 and held it in 4 quarters. The position peaked at $2.58M in Q4 2024. 125 funds tracked by Wall St. Rank hold PRME as of Q1 2025.

  • Westwood Holdings Group reported no remaining Prime Medicine position as of Q1 2025 after selling out during the quarter.
  • Westwood Holdings Group sold 883,129 Prime Medicine shares in Q1 2025, an estimated $2.58M.
  • Westwood Holdings Group first reported a position in Prime Medicine in Q1 2024 and held it in 4 quarters.
  • Westwood Holdings Group's Prime Medicine position peaked at $2.58M in Q4 2024.
  • 125 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2025.

Based on Westwood Holdings Group's 13F filing for Q1 2025, filed 9 May 2025.